Baxter Initiates Worldwide Voluntary Recall
Baxter International recalls dextrose injection and four sodium chloride injections.
Baxter International has initiated a voluntary recall to the hospital/user level of one lot of 5% dextrose injection, USP and four lots of 0.9% sodium chloride injection, USP due to particulate matter found in the solutions. There have been no reported adverse events associated with this issue to date, and the root cause of this recall has been identified and resolved.
Products affected by this recall were packaged in flexible plastic containers with 96 containers per carton. Affected product was distributed to healthcare centers and distributors in Saudi Arabia, Singapore, United Arab Emirates, and the United States and Puerto Rico.
Baxter has notified customers, who are being directed not to use product from the recalled lots. Customers that have product affected by this recall should stop use and arrange for return. The affected lots were distributed to customers between May 2012 and October 2013.
Source: Baxter International
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
